


## Autophagy-IN-1

Cat. No.:	HY-150636
Molecular Formula:	C <sub>23</sub> H <sub>25</sub> NO <sub>7</sub>
Molecular Weight:	427.45
Target:	Autophagy; Apoptosis
Pathway:	Autophagy; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Autophagy-IN-1 is a potent autophagy/mitophagy inhibitor, acts by selectively increasing the autophagic flux while blocking the autophagosome-lysosome fusion in cancer cells. Autophagy-IN-1 can induce apoptosis and cell cycle arrest. Autophagy-IN-1 significantly inhibits tumor growth in an HCT116 xenograft mouse model and with low toxicity. Autophagy-IN-1 can be used for researching colorectal cancer <sup>[1]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	Autophagy, Apoptosis <sup>[1]</sup>																
<b>In Vitro</b>	<p>Autophagy-IN-1 (compound 6) (1 and 5 μM; 8 h) induces apoptosis of HCT116 cells concentration-dependently<sup>[1]</sup>. Autophagy-IN-1 (0.5, 1, 5 and 10 μM; 6 h) decreases pro-PARP1, pro-caspase 8 and pro-caspase 3; increases Cleaved-PARP1, Cleaved-caspase 8 and Cleaved-caspase 3 concentration-dependently<sup>[1]</sup>. Autophagy-IN-1 increases LC3B-II, p62, and LAMP1 in HCT116 and SW620 cells, and increases number of autophagic/mitophagic vacuoles in HCT116 cells<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p><b>Apoptosis Analysis<sup>[1]</sup></b></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HCT116 cells</td> </tr> <tr> <td>Concentration:</td> <td>1 and 5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>8 h</td> </tr> <tr> <td>Result:</td> <td>Induced 10.11% and 33.52% apoptosis of HCT116 cells at 1 μM and 5 μM.</td> </tr> </table> <p><b>Western Blot Analysis<sup>[1]</sup></b></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HCT116 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.5, 1, 5 and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Decreased pro-PARP1, pro-caspase 8 and pro-caspase 3; increased Cleaved-PARP1, Cleaved-caspase 8 and Cleaved-caspase 3 concentration-dependently.</td> </tr> </table> <p><b>Cell Autophagy Assay<sup>[1]</sup></b></p>	Cell Line:	HCT116 cells	Concentration:	1 and 5 μM	Incubation Time:	8 h	Result:	Induced 10.11% and 33.52% apoptosis of HCT116 cells at 1 μM and 5 μM.	Cell Line:	HCT116 cells	Concentration:	0.5, 1, 5 and 10 μM	Incubation Time:	24 h	Result:	Decreased pro-PARP1, pro-caspase 8 and pro-caspase 3; increased Cleaved-PARP1, Cleaved-caspase 8 and Cleaved-caspase 3 concentration-dependently.
Cell Line:	HCT116 cells																
Concentration:	1 and 5 μM																
Incubation Time:	8 h																
Result:	Induced 10.11% and 33.52% apoptosis of HCT116 cells at 1 μM and 5 μM.																
Cell Line:	HCT116 cells																
Concentration:	0.5, 1, 5 and 10 μM																
Incubation Time:	24 h																
Result:	Decreased pro-PARP1, pro-caspase 8 and pro-caspase 3; increased Cleaved-PARP1, Cleaved-caspase 8 and Cleaved-caspase 3 concentration-dependently.																

	<table border="1"> <tr> <td>Cell Line:</td> <td>HCT116, SW620, and NCM460 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.5, 1, 5 and 10 <math>\mu</math>M</td> </tr> <tr> <td>Incubation Time:</td> <td>0, 1, 2, 4, 9, 12 and 24 h</td> </tr> <tr> <td>Result:</td> <td>Led to a time- and dose-dependent increase of the levels of LC3B-II, p62, and LAMP1 in HCT116 and SW620 cells, and increased number of autophagic/mitophagic vacuoles in HCT116 cells.</td> </tr> </table>	Cell Line:	HCT116, SW620, and NCM460 cells	Concentration:	0.5, 1, 5 and 10 $\mu$ M	Incubation Time:	0, 1, 2, 4, 9, 12 and 24 h	Result:	Led to a time- and dose-dependent increase of the levels of LC3B-II, p62, and LAMP1 in HCT116 and SW620 cells, and increased number of autophagic/mitophagic vacuoles in HCT116 cells.
Cell Line:	HCT116, SW620, and NCM460 cells								
Concentration:	0.5, 1, 5 and 10 $\mu$ M								
Incubation Time:	0, 1, 2, 4, 9, 12 and 24 h								
Result:	Led to a time- and dose-dependent increase of the levels of LC3B-II, p62, and LAMP1 in HCT116 and SW620 cells, and increased number of autophagic/mitophagic vacuoles in HCT116 cells.								
<b>In Vivo</b>	<p>Autophagy-IN-1 (50 and 100 mg/kg; IP, daily for 15 days) significantly inhibits tumor growth in an HCT116 xenograft mouse model<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male BALB/c nude mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>50 and 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>IP, daily for 15 days</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited tumor growth and did not observe weight loss.</td> </tr> </table>	Animal Model:	Male BALB/c nude mice <sup>[1]</sup>	Dosage:	50 and 100 mg/kg	Administration:	IP, daily for 15 days	Result:	Significantly inhibited tumor growth and did not observe weight loss.
Animal Model:	Male BALB/c nude mice <sup>[1]</sup>								
Dosage:	50 and 100 mg/kg								
Administration:	IP, daily for 15 days								
Result:	Significantly inhibited tumor growth and did not observe weight loss.								

## REFERENCES

[1]. Yang ST, et al. Development of Strigolactones as Novel Autophagy/Mitophagy Inhibitors against Colorectal Cancer Cells by Blocking the Autophagosome-Lysosome Fusion. J Med Chem. 2022 Jul 19.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA